Philip Hempleman, Ardsley Partners Initiate Position in Supernus Pharmaceuticals Inc (SUPN)

Philip Hempleman has become a fan of Supernus Pharmaceuticals Inc (NASDAQ:SUPN). According to a recent filing with the Securities and Exchange Commission, Hempleman’s fund, Ardsley Partners, has initiated a position in Supernus Pharmaceuticals. The fund has acquired 1.93 million shares, which represents approximately 5.7% of the company’s common stock. Considering Supernus Pharmaceuticals’ current price of $6.65 per share, Ardsley’s stake is worth approximately $12.8 million.

Anand Parekh has also recently joined the Supernus Pharmaceuticals Inc (NASDAQ:SUPN) fan club. During the third quarter of 2013, Parekh and his fund, Alyeska Investment Group, have initiated a new position and have bought 100,000 shares valued at $733,000. Israel Englander has almost doubled his fund’s holding of this stock during Q3 and Millennium Management now holds 181,221 shares worth approximately $1.3 million. Samuel Isaly is not so optimistic and has actually dumped 74% of the shares his fund held at the end of the second quarter. Orbimed Advisors’ stake amasses 639,400 shares reportedly worth $4.68 million.

The current price of $6.65 per share is not far away from the $7.39 per share at the beginning of the year. Nevertheless, the stock registered notable fluctuations, achieving a low of $4.45 in April and a high of $8.4 in August. Supernus Pharmaceuticals Inc (NASDAQ:SUPN) has a market cap of $225 million and does not pay a dividend. For the three months ended September 30, 2013, the company posted revenues of $1.25 million, 14 times more than for the same period last year, and a loss per share $0.78. Jack Khattar, President and Chief Executive Officer, commented:

As we expected in the third quarter we received approval by the FDA for Trokendi XR(TM) and were able to launch it one week later. Our business is now experiencing accelerated growth with product shipments to wholesalers reaching $13.8 million by the end of the third quarter and $17.9 million by the end of last week. Oxtellar XR(TM) prescriptions have doubled in the third quarter as compared to the second quarter and Trokendi XR(TM) is off to a great start. Our Company continues to execute very well on our two product launches

Disclosure: none

Recommended reading:

Hedge Fund News: David Tepper, George Soros & Man Group

GAMCO Goes Activist on Ascent Capital Group Inc (ASCMA); Proposes a Vote Regarding the Company’s Poison Pill

Anadarko Petroleum Corporation (APC), Schlumberger Limited. (SLB) Among 5 Energy Stocks That Hedge Funds Love